Prothena Corp PLC PRTA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
-
Prothena to Report First Quarter 2026 Financial Results on May 7
-
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
-
Prothena Announces Leadership Team Updates
-
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026
Trading Information
- Previous Close Price
- $8.29
- Day Range
- $8.45–8.71
- 52-Week Range
- $5.54–11.69
- Bid/Ask
- $8.62 / $8.65
- Shares Outstanding
- 52.35M
- Market Cap
- $452.33M
- Volume/Avg
- 195,286 / 507,257
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.67
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 1.63%
Company Profile
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 67
- Website
- https://www.prothena.com
Valuation
|
Metric
|
PRTA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.40 |
Price/Sales | 7.67 |
Price/Cash Flow | — |
Price/Earnings
PRTA
Financial Strength
|
Metric
|
PRTA
|
|---|---|
Quick Ratio | 10.13 |
Current Ratio | 10.43 |
Interest Coverage | — |
Quick Ratio
PRTA
Profitability
|
Metric
|
PRTA
|
|---|---|
Return on Assets (Normalized) | −25.75% |
Return on Equity (Normalized) | −30.02% |
Return on Invested Capital (Normalized) | −32.37% |
Return on Assets
PRTA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Clzrqdlj | Cvyxbh | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mdqcmlzn | Wtyzpmn | $64B | |||
| argenx SE ADR
ARGX
| Btsmrbls | Wvdxx | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Fxldnskt | Gndvry | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Yzfbmwxcrh | Ztnrlpk | $24B | |||
| BioNTech SE ADR
BNTX
| Ftbtdcjkf | Jyk | $23B | |||
| Incyte Corp
INCY
| Jtdthqhly | Zjsmc | $22B | |||
| Moderna Inc
MRNA
| Gfrqzczr | Tcbr | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Zkmpyrqv | Fnh | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Twdmsrkh | Gcfgs | $13B |
United States